SECURITIES AND EXCHANGE COMMISSION
                            WASHINGTON, D.C.  20549

                                  FORM 10-QSB

                     FOR QUARTER ENDED SEPTEMBER 30, 1998

                QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D)
                  OF THE SECURITIES AND EXCHANGE ACT OF 1934

                        COMMISSION FILE NUMBER 1-10768
                                               -------


                      MEDIWARE INFORMATION SYSTEMS, INC.
            (Exact name of registrant as specified in its charter)

     New  York          11-2209324
     (State  of  other  Jurisdiction  of          (I.R.S.  Employer
     incorporation  or  organization)          Identification  Number)


     1121  Old  Walt  Whitman  Road
     Melville,  New  York                                   11747-3005
     (Address  of  Principal  Executive  Officer)          (Zip  Code)



                                (516) 423-7800
             (Registrant's telephone number, including area code)




Indicate  by  check  mark  whether  the  registrant  (1) has filed all reports
required  to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934  during  the  preceding  12  months  (or for such shorter period that the
registrant was required to file such reports) and (2) has been subject to such
filing  requirements  for  the  past  90  Days.     Yes      X       No 
                                                          ------

As  of  September 30, 1998, there were 6,051,000 shares of Common Stock, $0.10
par  value,  of  the  registrant  outstanding.

<PAGE>


                      MEDIWARE  INFORMATION  SYSTEMS,  INC.

                                     INDEX

Part  I.   Financial  Information                                         Page
                                                                          ----


ITEM  1.   Financial  Statements
           Consolidated Balance Sheets as of September 30, 1998
           (unaudited) and June 30, 1998 (audited)                           2

           Consolidated Statements of Operations
           for the three months ended
           September 30, 1998 & 1997 (unaudited)                             3

           Consolidated Statements of Cash Flows
           for the three months ended
           September 30, 1998 & 1997 (unaudited)                             4

           Notes to Financial Statements                                     5


ITEM  2.   Management's Discussion and Analysis of Financial
           Condition and Results of Operations                               6

Signature Page                                                               9

Exhibit  11
Schedule of Computation of Net Income per Share                             10

<PAGE>

<TABLE>
<CAPTION>

                         MEDIWARE INFORMATION SYSTEMS, INC. AND SUBSIDIARIES
                                   CONSOLIDATED BALANCE SHEET
                                    AS AT SEPTEMBER 30, 1998

                                         (UNAUDITED)
<S>                                                                      <C>           <C>
                                                                                 <C>           <C> 
                                                                             Sep-30        Jun-30
                                                                         ------------  ------------
                        ASSETS                                                1998          1998 
                       --------                                          ------------  ------------

Current assets:
   Cash and cash equivalents                                             $ 4,897,000   $ 4,681,000 
   Accounts receivable, less estimated doubtful accounts of
     $489,000 at September 30, 1998 and $490,000 at June 30, 1998          9,160,000     7,485,000 
   Inventories                                                               463,000       331,000 
   Deferred Tax Asset                                                        550,000       550,000 
   Prepaid expenses and other current assets                                 508,000       514,000 
                                                                         ------------  ------------
        Total current assets                                              15,578,000    13,561,000 

   Fixed assets, at cost, less accumulated depreciation of $2,184,000
      at September 30, 1998 and $2,058,000 at June 30, 1998                1,493,000     1,170,000 
   Capitalized software costs                                              2,772,000     2,444,000 
   Excess of cost over fair value of net assets acquired, net of
      accumulated amortization of $1,183,000 at September 30, 1998
      and $1,091,000 at June 30, 1998                                      6,690,000     5,853,000 
   Purchased technology less accumulated amortization of $2000 at
      September 30, 1998                                                     496,000               
   Other assets                                                              133,000       719,000 
                                                                         ------------  ------------
                                                                         $27,162,000   $23,747,000 
                                                                         ============  ============

                        LIABILITIES
                       -------------

Current liabilities:
   Accounts payable                                                      $ 1,250,000   $ 1,176,000 
   Notes payable                                                           4,450,000     4,600,000 
   Accrued expenses and other current liabilities                          3,410,000     2,618,000 
   Advances from customers                                                 4,673,000     3,132,000 
   Current portion of capital leases payable                                   9,000         9,000 
                                                                         ------------  ------------
        Total current liabilities                                         13,792,000    11,535,000 
   Advances from customers - long term                                        10,000         7,000 
   Other liabilities - long term                                             106,000 
   Capital leases payable, less current portion                               13,000        15,000 
                                                                         ------------  ------------
        Total liabilities                                                 13,921,000    10,825,000 
                                                                         ------------  ------------

                        STOCKHOLDERS' EQUITY
                       ----------------------

Preferred stock - $.01 par value; authorized 10,000,000 shares; none
    issued and outstanding
Common stock - $.10 par value;  authorized 12,000,000 shares; issued
    and outstanding; 6,051,000 shares at September 30, 1998 and
    5,591,000 shares at June 30, 1998                                        605,000       559,000 
Unearned compensation                                                        (41,000)      (51,000)
Cumulative foreign currency translation adjustment                            48,000        36,000 
Additional paid-in capital                                                20,953,000    16,264,000 
(Deficit)                                                                 (8,324,000)   (4,618,000)
                                                                         ------------  ------------
        Total stockholders' equity                                        13,241,000    12,190,000 
                                                                         ------------  ------------
                                                                         $27,162,000   $23,747,000 
                                                                         ============  ============
</TABLE>
<PAGE>

<TABLE>
<CAPTION>

                  MEDIWARE INFORMATION SYSTEMS, INC. AND SUBSIDIARIES
                      CONSOLIDATED STATEMENTS OF OPERATIONS
                                  (UNAUDITED)

                                                  Three Months Ended September  30,
                                                  ---------------------------------
                                                             (unaudited)
                                                          1998          1997
                                                      -------------  -----------
<S>                                                   <C>            <C>          <C>
                                                               <C>          <C> 
REVENUES:
    System sales                                      $  2,923,000   $1,863,000 
    Services                                             3,205,000    3,096,000 
                                                      -------------  -----------

      Total revenues                                     6,128,000    4,959,000 
                                                      -------------  -----------
COSTS AND EXPENSES:
    Cost of systems                                        901,000      665,000 
    Cost of services                                       907,000      747,000 
    Purchased research and development                   4,553,000 
    Software development costs                             663,000      584,000 
    Selling, general and administrative                  2,608,000    2,191,000 
                                                      -------------  -----------
     Total Costs & Expenses                              9,632,000    4,187,000 

Earnings (loss) before interest and taxes               (3,504,000)     772,000 
Interest and other income                                   41,000       45,000 
Interest (expense)                                         (93,000)    (156,000)
                                                      -------------  -----------
Earnings (loss) before taxes                            (3,556,000)     661,000 
Provision for income taxes                                 150,000       38,000 
                                                      -------------  -----------
NET EARNINGS (LOSS)                                    ($3,706,000)  $  623,000 
                                                      =============  ===========
Basic earnings (loss) per share                             ($ .66)       $ .12 
Diluted earnings (loss) per share                           ($ .66)       $ .10 
Weighted average shares outstanding                      5,630,000    5,086,000 
                                                      =============  ===========
Average shares outstanding assuming
dilution                                                 5,630,000    6,312,000 
                                                      =============  ===========
</TABLE>
<PAGE>


<TABLE>
<CAPTION>

                         MEDIWARE INFORMATION SYSTEMS, INC. AND SUBSIDIARIES
                               CONSOLIDATED STATEMENTS OF CASH FLOWS

                                                                              Three Months Ended
                                                                             --------------------
<S>                                                                    <C>                   <C>
                                                                                  <C>           <C> 
                                                                             Sep-30           Sep-30
                                                                              1998             1997 
                                                                        --------------  ------------
                                                                           (unaudited)   (unaudited)
CASH FLOWS FROM OPERATING ACTIVITIES:
   Net earnings (loss)                                                    ($3,706,000)    $ 623,000 
   Adjustments to reconcile net earnings (loss) to net cash
   provided by operating activities: (excluding Informedics acquisition)
     Purchased research and development                                     4,553,000
     Shares issued to directors                                                25,000
     Compensatory stock options issued to consultants                          10,000
     Provision for doubtful accounts                                            3,000       109,000 
     Depreciation and amortization                                            399,000       196,000 
     Changes in operating assets and liabilities
         Accounts receivable                                               (1,319,000)     (963,000)
         Inventory                                                           (117,000)        8,000 
         Prepaid and other assets                                            (156,000)     (147,000)
         Accounts payable, accrued expenses and customer
         advances                                                             916,000     1,450,000 
                                                                        -------------   ------------
            Net cash provided by operating activities                         608,000     1,276,000 
                                                                        -------------   ------------

CASH FLOWS FROM INVESTING ACTIVITIES:
   Acquisitions of fixed assets                                              (396,000)      (78,000)
   Cash received from acquisition of Informedics                              653,000
   Capitalized software costs                                                (519,000)     (192,000)
                                                                        -------------   ------------
            Net cash (used in) investing activities                          (262,000)     (270,000)
                                                                        -------------   ------------

CASH FLOWS FROM FINANCING ACTIVITIES:
   Proceeds from exercise of options and warrants                              10,000        32,000 
   Proceeds of private placement                                                          2,160,000 
   Repayment of debt                                                         (152,000)     (902,000)
                                                                        -------------   ------------
          Net cash (used in) provided by financing
          activities                                                         (142,000)    1,290,000 
                                                                        -------------   ------------

Effect of exchange rate changes on cash                                       12,000

NET INCREASE IN CASH AND CASH EQUIVALENTS                                     216,000     2,296,000 
Cash and cash equivalents, beginning of period                              4,681,000     1,935,000 
                                                                        -------------   ------------

CASH AND CASH EQUIVALENTS, END OF PERIOD                                  $ 4,897,000   $ 4,231,000 
                                                                         ============  =============

Supplemental disclosures of cash flow information:
    Cash paid during the period for:
    Interest                                                              $    79,000   $   197,000 
    Income taxes                                                          $    62,000   $    26,000 
</TABLE>
<PAGE>

              MEDIWARE INFORMATION SYSTEMS, INC., & SUBSIDIARIES
                    NOTES TO UNAUDITED FINANCIAL STATEMENTS

1.          FINANCIAL    STATEMENTS:
            -----------------------

     In  the  opinion of management, the accompanying unaudited, consolidated,
condensed  financial  statements  contain all adjustments necessary to present
fairly the financial position of the Company and its results of operations and
cash  flows for the interim periods presented.  Such financial statements have
been condensed in accordance with the applicable regulations of the Securities
and  Exchange Commission ("SEC") and therefore, do not include all disclosures
required  by  generally  accepted  accounting  principles.     These financial
statements  should be read in conjunction with the Company's audited financial
statements  for  the year ended June 30, 1998 included in the Company's annual
report  filed  on  Form  10-KSB.

     The  results  of operations for the three months ended September 30, 1998
are  not  necessarily  indicative of the results to be expected for the entire
fiscal  year.


2.          EARNINGS  (LOSS)  PER  SHARE:
            -----------------------------

     The  Company  adopted  the  provisions  of  the  Statement  of  Financial
Accounting Standards ("SFAS") No. 128, "Earnings per Share" in the preparation
of  the financial statements included in this Quarterly Report on Form 10 QSB.
In  accordance with the provisions of SFAS No. 128, the Company is required to
report both "basic" and "diluted" earnings per share and to restate previously
reported  earnings per share amounts to conform to the provisions of SFAS 128.
Basic  earnings per share have been computed using the weighted average number
of shares of common stock of the Company ("Common Stock") outstanding for each
period  presented.   In  Fiscal 1998, the dilutive effect of stock options and
other  common  stock  equivalents  is  included  in the calculation of diluted
earnings  per  share using the treasury stock method.  For Fiscal 1999, common
stock equivilents are not included in the calculation of loss per share as the
effect  would  be  anti-dilutive.

3.          ACQUISITION:
            ------------

          In  September,  1998,  the  Company  acquired  Informedics,  Inc.
("Informedics")  in  exchange for 439,525 shares of the Company's common stock
on  the basis of 1 Company share for each 6.3 Informedics shares.  Informedics
is  developing  a  Web-enabled  software  system technology and also develops,
markets  and  supports  a  line  of  stand-alone  computer-based  management
information  systems  for  use  in  the blood bank and clinical departments of
hospitals.    The  cost  of  the  acquisition,  which  was  accounted for as a
purchase,  aggregated  $7,100,000,  including  acquisition  costs of $801,000,
assumed  liabilities  of  $1,599,000 and $4,700,000 of common stock issued and
options  assumed  based  on  the market price of the Company's common stock in
December  1997,  when the  acquisition  agreement  was  entered  into.  Assets
acquired  aggregated  $2,547,000  including  $917,000 of goodwill, $498,000 of
technology  and  $653,000  of  cash.

<PAGE>

The  following  unaudited  pro forma financial information gives effect to the
merger  as  if it had occurred at the beginning of the first quarter of fiscal

years  1998  and 1999.  A non-recurring charge of approximately $4,553,000 for
in-process  research  and  development  which  was  recorded by the Company on
consummation of the acquisition and the fiscal 1998 reversal of net tax assets
on  Informedics  financial statements has not been considered in the pro forma
results.  The pro forma financial information does not necessarily reflect the
results of operations that would have occurred had the acquisition taken place
during  such  periods.

<TABLE>
<CAPTION>

              Quarter Ended September 30,
              ----------------------------            
                                   1997             1998
                                 ---------       ----------
<S>                         <C>                    <C>  <C>
                                       <C>  <C>         <C>
Revenue:                      $  5,710,000       $6,747,000
                              ============       ==========
Net earnings                  $    540,000       $  848,000
                              ============       ==========
Basic earnings per share               .10              .14
Diluted earnings per share             .08              .13

</TABLE>

4.          RECENT    ACCOUNTING    PRONOUNCEMENTS:
            --------------------------------------

      In  October 1997, the American Institute of Certified Public Accountants
issued  Statement of Position 97-2, "Software Revenue Recognition" (SOP 97-2).
SOP  97-2 is effective for transactions entered into in fiscal years beginning
after  December  15,  1997.  "Retroactive application of the provisions of SOP
97-2  is  prohibited."

     Accordingly  the Company has adopted SOP 97-2 in its financial statements
for  the  quarter  ended  September, 1998.  Such adoption had no effect on the
Company's  results  of  operations.

ITEM    2.     MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
               RESULTS  OF  OPERATIONS.

FORWARD-LOOKING  STATEMENTS:

     Certain  statements  made  in  this  report  are or imply forward-looking
statements.       Such forward looking statements are not guarantees of future
performance and are subject to risks and uncertainties that could cause actual
results  to  differ  materially  from  those  expressed  or  implied  in  the
forward-looking  statements.      Certain of these risks and uncertainties are
expressed  in  the  Risk  Factors  discussed in the Prospectus included in the
Registration  Statement  on  Form  SB-2, File No.  333-18277, especially those
under  the  headings    "Working  Capital  Deficiency; Restrictive Covenants,"
"Variability  of  Operating  Results,"    "Hospital  Purchase  Procedures,"
"Acquisition,"  "Competition,"    "Technological  Obsolescence;  Marketing and
Acceptance  of  New  Products,"    "Product  Protection"    and    "Government
Regulation."

RESULTS  OF  OPERATIONS:

     During  the  quarter  the  Company  acquired  Informedics,  Inc.
("Informedics").    Informedics  develops,  markets  and  supports  a  line of
stand-alone computer-based management information systems for use in the blood
bank  and  clinical  departments  of hospitals.  Additionally, Informedics has
been  developing a Web-enabled software system technology called IntraMed.net.
This internet/intranet oriented software is intended to provide the ability to
extract  data  from installed legacy computer systems and then store, download
or manipulate the data.  While no assurances can be made, the Company believes
that Informedics' Web-enabling technology, when implemented and sold to future
and  existing  customers,  will  expand  the  reach  of  the  three  clinical
departments  (Blood  Bank,  Pharmacy  and  Surgical  Suite) Mediware currently
addresses.    The  acquisition  was  completed  in  September,  1998,  and was
accounted  for  as  a purchase.  The Company consolidated the acquired balance
sheet  and  results  of  operations  in the first quarter of fiscal 1999.  The
Company's  operating results include the results of operations of Informedics'
from  the  date  of  acquisition  which  consisted of revenues of $47,000  and
operating expenses of $40,000.   Additionally, the Company recorded a one-time
acquisition  related  charge  of  $4,553,000  for  in-process  research  and
development related to the estimated fair value of the IntraMed.net technology.

     Total  Company  revenues  increased  by 23.6% or $1,169,000 for the first
three  months  of fiscal  1999  as compared to the same period in fiscal 1998.
This  increase was impacted by all product lines but was significantly related
to  revenue  gains  in  the  Company's  Blood  Bank  Division.

     System  sales  increased  by  56.9% or $1,060,000 in the first quarter of
fiscal  as  compared  to  the  same period in the prior year.   For the period
ended  September  30,  1998  the increase is primarily due to increased system
sales  in  the  Company's  Pharmacy  and  Blood  Bank  Divisions.

     Services  revenues  increased 3.5% or $109,000 to $3,205,000 in the first
three months of fiscal 1999 as compared to $3,096,000 for the same period last
year.    The  increase  is  primarily due to increased service revenues at the
Company's  Hemocare  Division.

     Cost  of  systems  includes the cost of computer hardware and sublicensed
software  purchased  from  computer  and software manufacturers by Mediware as
part  of  its  complete  system  offering.  These costs can vary as the mix of
revenue  varies  between  high  margin  proprietary  software and lower margin
computer  hardware  and  sublicensed software components. Cost of systems were
30.8%  of  related  system  sales for the first three months of fiscal 1999 as
compared  to 35.7% of related system sales for the same period in fiscal 1998.
Cost  of  systems  increased  by  35.5% or $236,000 from $665,000 in the first
quarter  fiscal  1998  to  $901,000  in  the same period in fiscal 1999.  This
increase  in  cost is principally due to the change in mix between proprietary
licensed  software  (which  is  at  a  higher  gross  margin)  and third party
software/hardware  (which  has  a  lower  gross  margin)  within  the Pharmacy
division.

     Cost  of  services  includes the salaries of client service personnel and
communications  expenses along with the direct expenses.  The cost of services
will vary with technical employee activity changes between client services and
software development. Cost of services increased $160,000 from $747,000 in the
first  three  months of fiscal 1998 as compared to $907,000 in the same period
of  the  current fiscal year.   Cost of services were 28.3% of related revenue
for the three months ended September 30, 1998 vs. 24.1% of related revenue for
the  same  period  a year earlier. This increase in cost primarily reflects an
increase  in  technical field installation activities related to the Company's
Pharmacy  division.

     Software  development  costs include salaries, consulting, documentation,
office  and  other  expenses  incurred  in  product  development  along  with
amortization  of  software  development  cost.    Software  development  costs
increased  $79,000  or 13.5% from $584,000 in the first three months of fiscal
1998  to  $663,000  in the same period in fiscal 1999.  Expenditures  (amounts
including  both  capitalized  and  non-capitalized  expenditures and excluding
capitalized  software  amortization)  for  software  development for the first
three  months  of  fiscal  1999  were  approximately   $991,000 as compared to
$709,000  in  the  first three months of fiscal 1998.  Spending on development
has  increased  among  all company divisions but is principally focused on the
Company's  Pharmacy  division's  enhancements  to  its WORx product line.  The
Company  expects to continue this level of development spending with increased
focus  on  continued  product  enhancements  and  integration  of  Web-based
communications  technology.

     Selling,  general and administrative expenses include marketing and sales
salaries,  commissions, travel and advertising expenses.  Also included is bad
debt  expense;  legal,  accounting  and  professional fees; salaries and bonus
expense  for  corporate,  divisional,  financial  and  administrative  staff;
utilities,  rent,  communication  and other office expenses; and other related
direct  administrative expenses.  Selling, general and administrative expenses
increased  by   $417,000 or 19.0% from $2,191,000 in the first three months of
fiscal 1998 to $2,608,000 in the same period in fiscal 1999.  This increase in
cost is due to higher communications, travel, administrative, marketing, legal
and  professional  costs.    This  increase reflects the cost of  managing and
growing  the  Company.      Additionally,  the  increase  reflects  the higher
commission  costs  related  to  increased  sales  volume.

     Net  interest  expense  decreased    $59,000  or 53.2% in the first three
months  of  fiscal  1999  vs. the same period a year ago.  For the three-month
period  the  reduced interest expense is due to the $600,000 decrease of notes
payable  from  September  30,  1997  to  September  30,  1998.

     Net earnings were directly affected by the $4,553,000 one-time charge for
in-process  research  and  development  resulting in a net loss of $3,706,000.
Excluding  this  one time charge, net earnings for the quarter ended September
30, 1998 increased by 36.0% or $224,000 from $623,000 for the first quarter of
fiscal  1998  to  $847,000  for  the  same  period  in  fiscal  1999.

LIQUIDITY  AND  CAPITAL  RESOURCES:

     The Company's cash and cash equivalent position at September 30, 1998 was
$4,897,000, an increase of $216,000 from June 30, 1998.  At September 30, 1998
the current ratio was 1.1:1.   Current liabilities include $4,450,000 in notes
payable,  of  which $3,600,000 is owed to Continental Healthcare Systems, Inc.
("Continental").   The Continental note is due November 30, 1998.  The balance
in  notes  payable  at the end of September 30, 1998 was owed to two directors
and  another  person.     The Company is currently in negotiation with several
leading  institutions  seeking to obtain favorable terms in borrowing rates on
refinancing  portions or all of the Continental note.  While no assurances can
be  made,  it  is  anticipated  that  this  promissory  note  payment  will be
substantially financed through a commercial long-term loan at rates comparable
to  the existing note.  In addition to refinancing of the promissory note, the
Company  will review other financing needs and general cash requirements on an
on-going  basis.    The Company may require additional sources of liquidity to
fund  potential  acquisitions,  expanded  research and development costs along
with  other  financing  needs.


<PAGE>

                                  SIGNATURES

     Pursuant  to the requirements of the Securities Exchange Act of 1934, the
Registrant  has  duly  caused  this  report  to be signed on its behalf by the
undersigned,  thereunto  duly  authorized.


                                   MEDIWARE  Information  Systems,  Inc.
                                   -------------------------------------
                                              (Registrant)



November 19, 1998                  By:   /s/ John Esposito
    (Date)                               John  Esposito
                                         President and CEO





November 19, 1998                  By:   /s/ George J. Barry
    (Date)                               George J. Barry
                                         Chief Financial Officer

<PAGE>

<TABLE>
<CAPTION>

               MEDIWARE INFORMATION SYSTEMS, INC. AND SUBSIDIARIES

                                EXHIBIT 11

                SCHEDULE OF COMPUTATION OF NET INCOME PER SHARE

                                              Three months              Three months
                                                ended                      ended
                                             September 30,             September 30,
<S>                                                   <C>                 <C>
                                                                     <C>         <C>
                                                 1998                      1997
                                             ---------------         ---------------
Net Income                                    $ (3,706,000)               $  623,000
                                             ---------------              ----------
Weighted Average Share
Outstanding                                      5,630,000                 5,086,000
Effect of Dilutive
Securities: Common                            --------------              ----------
Stock Equivalents
(Options & Warrants)                             5,630,000                 6,312,000
Average shares
Outstanding assuming
dilution                                            ($ .66)                  $  0.12
                                              --------------              ----------
Basic earnings per share
Diluted earnings per
share                                               ($ .66)                  $  0.10
</TABLE>